Tag: ORGN

Turn Tax Selling Stocks into Tax Selling Bounce Stocks

by Fred Fuld III

A tax selling stock is a stock that is currently selling for a low price but was trading at much higher levels earlier in the year.

What is Tax Harvesting?

As the year-end approaches, many investors use the strategy called tax harvesting , which is selling stocks the have tanked to offset any gains that may have been established sometime during the year.

With strong selling, the price of stocks that have had big drops tends to fall far more than what would normally take place during the rest of the year.

What are Tax-Selling Bounce Stocks?

So traders and investors are on the lookout for tax selling bounce stocks that are heavily hit, hoping for a little (or big) bounce in January, once the tax selling is over.

Here are some stocks that are down over 75% year-to-date and have market caps in excess of $75 million. They are all based in the United States and re generating positive earnings.

CompanySymbolMarket CapP/EPrice
reAlpha Tech Corp.AIRE146.29M428.753.43
Ebix Inc.EBIX139.05M28.044.5
Eagle Pharmaceuticals IncEGRX75.18M6.365.79
Origin Materials IncORGN99.19M1.960.69

reAlpha Tech Corp., a real estate technology company with a focus on short-term rentals, operates under two main segments: Platform Services and Investment Services.

Platform Services offer AI-powered products and services to real estate professionals, including data analytics, property management tools, and automated property valuations. Investment Services connect investors with fractional ownership opportunities in short-term rental properties.

The company has recently launched a new AI-powered rental pricing tool and expanded its portfolio to include Miami, Florida. With growing revenue and a focus on artificial intelligence, reAlpha Tech Corp. may be well-positioned to benefit from the booming short-term rental market.

Ebix Inc. is a leading international supplier of on-demand software and e-commerce services, primarily focusing on the insurance, financial, travel, cash remittance, and healthcare industries. The company operates globally, providing end-to-end solutions ranging from infrastructure exchanges and carrier systems to agency systems and risk compliance solutions.

Ebix boasts a comprehensive portfolio of services including software development, consultancy services, life insurance, risk management, health and employee benefits, CRM, and applications software for property and casualty insurance. Its expertise lies in developing and deploying insurance and reinsurance exchanges on an on-demand basis using software-as-a-service (SaaS) enterprise solutions. These solutions cover a wide range, encompassing customer relationship management, front-end and back-end systems, and outsourced administrative and risk compliance services.

Ebix leverages its expertise in consulting, systems design and integration, IT and business process outsourcing, applications software, and web and application hosting to cater to the individual needs of various organizations. This comprehensive approach positions Ebix as a leading player in the on-demand infrastructure exchange market for insurance, financial, and healthcare industries.

Eagle Pharmaceuticals, Inc. is a fully diversified pharmaceutical company dedicated to advancing safe and effective treatments for patients, healthcare providers, and the healthcare system as a whole. The company focuses its efforts on critical care and oncology, developing and commercializing injectable products in areas where there are unmet medical needs.

Eagle’s portfolio consists of four approved products:

  • Argatroban: An injectable anticoagulant used to treat and prevent blood clots in patients with heparin-induced thrombocytopenia (HIT).

Ryanodex: The only FDA-approved treatment for exertional heatstroke, a life-threatening condition caused by excessive exertion in hot environments.

Belrapzo: A monoclonal antibody approved for the treatment of adult patients with chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin’s lymphoma (NHL) who have failed or are intolerant to bendamustine and rituximab.

Bendeka: A liposomal encapsulation of bendamustine, a chemotherapy drug used to treat patients with CLL and indolent NHL.


Origin Materials, Inc. is a leading carbon-negative materials company on a mission to enable the world’s transition to sustainable materials. Their innovative platform transforms the carbon found in sustainable biomass, like wood residues and agricultural waste, into useful materials like bioplastics, biofuels, and carbon black. This process eliminates the need for fossil resources and captures carbon in the process, making Origin’s products truly carbon-negative.

Origin’s technology boasts several significant advantages. Their bio-based materials offer comparable performance to traditional petroleum-based materials while significantly reducing greenhouse gas emissions. This makes them attractive to companies seeking to reduce their environmental footprint and contribute to a more sustainable future. Additionally, Origin’s platform is highly scalable, allowing them to produce large quantities of their products to meet the growing demand for sustainable materials.

Currently, Origin is focused on two key markets:

  • Advanced bio-textiles: These bio-based alternatives to traditional textiles can be used in a variety of applications, including clothing, automotive interiors, and medical textiles.
  • Carbon black: This essential material is used in a variety of industrial applications, including tires, rubber products, and inks. Origin’s bio-based carbon black offers superior performance and environmental benefits over traditional carbon black derived from fossil fuels.

Origin may be well-positioned to capitalize on the growing demand for sustainable materials.

Hopefully, another investor’s loss can be your gain. However, keep in mind that these are all very low cap stocks and they may have been dropping substantially for a reason.

Disclosure: Author didn’t own any of the above at the time the article was written.

Three Stocks Selling Below Cash per Share

by Fred Fuld III

Cash per share is a financial metric used in stock fundamental analysis to assess a company’s financial health and its ability to meet its short-term obligations. It represents the amount of cash a company has on hand per outstanding share of its common stock. This metric is calculated by dividing the total cash and cash equivalents a company holds by the number of outstanding common shares.

Cash per share is important in fundamental analysis for several reasons:

  1. Liquidity Assessment: It provides insights into a company’s liquidity, indicating how much cash is readily available to cover its immediate financial needs. Higher cash per share suggests better liquidity and a lower risk of financial distress.
  2. Risk Mitigation: Companies with a significant cash reserve per share are better positioned to weather economic downturns, financial crises, or unexpected expenses without resorting to debt or diluting shareholder equity.
  3. Investor Confidence: A high cash per share ratio can enhance investor confidence, as it signals that the company has the financial flexibility to invest in growth opportunities, pay dividends, or repurchase shares.
  4. Acquisition Potential: Companies with substantial cash per share are often viewed as attractive targets for mergers and acquisitions, as their cash reserves can be used to fund such activities.
  5. Capital Allocation: It can assist investors in evaluating a company’s capital allocation strategy. If a company is accumulating cash but not deploying it effectively, it may indicate that management lacks a clear plan for growth or shareholder value creation.
  6. Comparison: Cash per share can be used to compare a company’s financial strength with that of its peers in the same industry or sector. It helps investors identify companies with relatively stronger cash positions.

It’s important to note that while a high cash per share ratio can be a positive sign, excessively hoarding cash without deploying it effectively can be detrimental to shareholder returns. Investors typically consider cash per share in conjunction with other financial metrics and factors, such as earnings, debt levels, and the company’s overall business strategy, to make informed investment decisions.

In summary, cash per share is a fundamental metric that provides insights into a company’s financial strength, liquidity, and ability to weather economic challenges. It plays a crucial role in evaluating a company’s financial health and investment potential.

To give a specific example, if a company goes out of business today, and it’s stock is debt free and selling for less than the cash per share, even if all its real estate, machinery, inventory, and everything else is worthless, the shareholder would be guaranteed to make money.

You may wonder if you can still buy stocks selling below cash. Here is one example.

Origin Materials (ORGN), with a market cap of $202.4 million, is trading at 93% of the cash per share.

Origin Materials, Inc., founded in 2008 and headquartered in West Sacramento, California, is a company dedicated to the development and commercialization of sustainable materials and chemicals.

Their primary focus revolves around producing carbon-negative materials and chemicals using renewable feedstocks sourced from non-food biomass, such as wood and agricultural residues.

By leveraging innovative technologies, Origin Materials aims to create products with a net-negative carbon footprint, meaning they remove more carbon from the atmosphere than is emitted during their production. The company collaborates with various partners, including major consumer brands and chemical companies, to incorporate their sustainable materials into a wide array of products.

Origin Materials’ mission centers on environmental sustainability, offering eco-friendly alternatives to conventional materials and contributing to the reduction of industries’ environmental impact.

The stock has a reasonable price to earnings ratio of 7.69, and is selling at 53% of book value.

If you are looking for a stock with a larger market cap, and if you think the market for commercial real estate has bottomed out, Equity Commonwealth (EQC) is a real estate investment trust with a market cap of $2.07 billion. The stock is selling at 96% of its cash per share.

This REIT invests in commercial office properties and is based in Chicago.

The company is debt free, trades at 33.4 times earnings, and is trading at 92% of book value.

If you are looking for very high risk, ClearOne (CLRO) is a penny stock with a market cap of $19.57 million.

ClearOne, Inc. is a communication solutions company headquartered in Salt Lake City, Utah, USA, with a history dating back to its founding in 1983. Specializing in audio and visual collaboration technologies, ClearOne has established itself as a prominent player in the industry.

The company’s core focus revolves around providing cutting-edge solutions designed to enhance communication and collaboration in diverse professional settings.

ClearOne offers a comprehensive suite of products and services tailored for improving communication quality, whether in corporate conference rooms, educational institutions, huddle spaces, or remote work environments. This includes audio conferencing solutions, video conferencing systems, collaboration software, professional audio-visual integration capabilities, and unified communications integration.

ClearOne has earned recognition for its patented technologies in echo cancellation, noise reduction, and audio processing, all contributing to the enhancement of audio quality.

Their mission is to simplify and elevate communication experiences for businesses, educational institutions, and government organizations, fostering productivity and seamless interaction.

The company has no long term debt, a very low P/E ratio less than 2, a decent price sales ratio of 0.98, and sells for 45% of book value.

Please note that while a low price-to-cash ratio may indicate good value, it should not be the sole factor considered in investment decisions. Conducting thorough research and due diligence, evaluating the company’s fundamentals, assessing its competitive position, and considering other financial metrics are essential to make solid investment choices.

Disclosure: Author didn’t own any of the above at the time the article was written. These stocks are very low cap and should be considered extremely speculative.